SCP
AARD

SymBiosis Capital Partners’s Aardvark Therapeutics AARD Stock Holding History

SymBiosis Capital Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-476,595
Closed -$6.26M – 12
2025
Q4 		$6.26M Buy
+476,595
New +$5.95M 5.71% 8

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SymBiosis Capital Partners's AARD Position: Q1 2026 in Review

SymBiosis Capital Partners sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 476,595 shares — an estimated $6.26M sold.

SymBiosis Capital Partners first reported a position in AARD in Q4 2025 and held it in 1 quarter. The position peaked at $6.26M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • SymBiosis Capital Partners reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SymBiosis Capital Partners sold 476,595 Aardvark Therapeutics shares in Q1 2026, an estimated $6.26M.
  • SymBiosis Capital Partners first reported a position in Aardvark Therapeutics in Q4 2025 and held it in 1 quarter.
  • SymBiosis Capital Partners's Aardvark Therapeutics position peaked at $6.26M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.